Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $394552.00 · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
3.0x
↓EV/EBITDA
3.8x
↓ROE
8.0%
↑Gross Margin
68.4%
↑Debt/Equity
0.95
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+55.3%
FCF CAGR
—
FCF margin
-30.4%
FCF / Net income
-4.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.6M · net income $864995.0 · FCF $-4.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.6M | $13.6M | $11.8M | $10.1M | $3.6M |
| Net Income | $864995.00 | $864995.00 | $-4.1M | $-2.0M | $-7.1M |
| EBITDA | $3.3M | $3.3M | $-2.6M | $-938920.00 | $-6.0M |
| EPS | 0.01 | 0.01 | -0.03 | -0.02 | -0.07 |
| Gross Margin | 68.4% | 68.4% | 30.6% | 29.6% | 1.6% |
| Operating Margin | 22.8% | 22.8% | -9.4% | -14.3% | -140.3% |
| Net Margin | 6.4% | 6.4% | -35.1% | -20.1% | -196.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.95 | 0.95 | 0.82 | 0.58 | 0.39 |
| Current Ratio | 2.76 | 2.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.1M | $-4.1M | $781460.00 | $394552.00 | $-5.8M |
| Returns | |||||
| ROE | 8.0% | 8.0% | -55.4% | -18.2% | -73.3% |
| Valuation | |||||
| P/E | 3.00 | 3.00 | — | — | — |
| EV/EBITDA | 3.81 | 3.81 | — | — | — |
| P/B | 0.36 | 0.36 | 0.61 | 1.13 | 3.39 |
| Growth & Yield | |||||
| Revenue Growth | 15.5% | 15.5% | 16.9% | 177.2% | — |
| EPS Growth | 133.3% | 133.3% | -50.0% | 71.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-35.7%
EPS terminal req.
$0.00
Spread vs growth
169.0%
5Y implied EPS CAGR
-20.3%
EPS terminal req.
$0.00
Spread vs growth
153.6%
10Y implied EPS CAGR
-6.4%
EPS terminal req.
$0.01
Spread vs growth
139.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → 0.01
Residual
-33.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.